Search Results for "Colchicine And Rivaroxaban"

23:24 EDT 17th April 2015 | BioPortfolio

Matching Channels


Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

BRIEF-Hikma Pharma says preparing to distribute Colchicine

* Prepare to distribute its colchicine, which it will market under brand name mitigare

Takeda’s Take On Patent Certification Rules In Colchicine Dispute Rejected

A federal judge tosses Takeda’s suit against FDA, finding Hikma did not need to reference Takeda’s Colcrys or certify Colcrys patents to obtain approval of its colchicine product.

Rivaroxaban Viable as Alternative Anticoagulant for Cardioversion

The oral anticoagulant rivaroxaban appears to safely and effectively prevent the risk of stroke associated with cardioversion in patients with atrial fibrillation, according to a randomized trial of 1...

Hikma to launch colchicine in USA as Takeda’s injunction fails

Jordon-headquartered Hikma Pharmaceuticals saw its shares rise 4.2% to a record high of £23.80, after a USA appeals court rejected Japanese drug major Takeda Pharmaceutical’s bid to bock the firm...

Rivaroxaban vs Vitamin K Antagonists for Cardioversion in AF

Does oral rivaroxaban help to fast-track patients for cardioversion? European Heart Journal

Prasco to market authorized colchicine generic in the US

US generics maker, Prasco Laboratories (Prasco), announced on 12 January 2015 that it had entered into an alliance with the US subsidiary of Japanese pharmaceutical company, Takeda, to distribute an a...

NICE Advisors Recommend Rivaroxaban (Xarelto) for ACS Patients

Although not yet final, an interim recommendation from a National Institute for Health and Care Excellence advisory committee says rivaroxaban in ACS patients is a cost-effective use of National H...

Antidote Reverses Anticoagulation Activity of Rivaroxaban: ANNEXA-R

The antidote immediately and significantly reversed the anticoagulation activity of rivaroxaban, making this study the second successful test of the antidote with the factor Xa inhibitors. Heart...

Matching PubMed Articles

Colchicine: Old and New.

Although colchicine has been a focus of research, debate and controversy for thousands of years, it was only approved by the United States Food and Drug Administration in 2009. Over the past decade, a...

Of men and meals.

Rivaroxaban is increasingly used to treat patients with acute venous thromboembolism (VTE), a potentially life-threatening condition. Since absorption of rivaroxaban decreases from nearly 100% to 66% ...

Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 - systematic review and meta-analysis.

The purpose of this study was to investigate and summarize available evidence on the efficacy and safety of colchicine for pericarditis prevention. Disease recurrence is the major and most common comp...

Rivaroxaban in atrial fibrillation cardioversion: insights from the X-VeRT trial.

ABSTRACT  Vitamin K antagonists (VKAs) have traditionally been the standard of care for the thromboprophylactic anticoagulation of patients with nonvalvular atrial fibrillation (NVAF) undergoing car...

Rivaroxaban for Treatment of Venous Thromboembolism in Older Adults.

Rivaroxaban is a factor Xa inhibitor recently approved for use in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Older adults are at an increased risk for venous thromboembol...

Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement